Filter By Product:

Myriad myChoice®

What is Myriad?

Myriad is a molecular diagnostic company that is dedicated to saving lives and improving the quality of life of patients worldwide through the discovery and commercialization of novel, transformative diagnostic products and services across major diseases.

What types of tests does Myriad offer?

At Myriad, we are dedicated to saving patients’ lives and improving quality of life by offering molecular and companion diagnostic tests that help healthcare professionals and their patients make better, more informed treatment decisions. Myriad offers healthcare professionals an array of genetic, prognostic and personalized medicine tests to help them:

  • Predict disease
  • Diagnose disease
  • Assess prognosis
  • Guiding Personalized Treatment

Myriad is working to empower providers and their patients with the knowledge they need at every stage of the healthcare journey. By continuously innovating to improve patient care through the development of new products across multiple medical specialties, we are changing the understanding and treatment of major diseases, including cancer, autoimmune diseases, diabetes and more.

Learn more about Myriad’s test offerings »

What is Myriad myChoice?

Myriad myChoice is one component of Myriad’s commitment to personalizing medicine by answering a pressing question in oncology, “how should I treat this disease?”

Explore Myriad’s myChoice Portfolio »

What if my patient’s testing isn’t covered by insurance?

Because patients and their families use test results to make life saving medical decisions, Myriad promises to provide affordable access to testing, a lifetime commitment to accurate results, and comprehensive support for ALL appropriate patients and their families.

If a patient encounters ANY financial hardship associated with their bill, Myriad will work directly with the patient toward their complete satisfaction.

Patients with questions regarding their Myriad bill or insurance Explanation of Benefits should contact Myriad rather than their health care provider. Myriad is here to help: 844-MYRIAD9 (844-697-4239) or billinghelp@myriad.com.

To learn more about The Myriad Promise visit www.MyriadPromise.com

Does Myriad have a financial assistance program? If so how does my patient qualify?

Because patients and their families use test results to make life saving medical decisions, Myriad promises to provide affordable access to testing, a lifetime commitment to accurate results, and comprehensive support for ALL appropriate patients and their families.

Myriad offers financial assistance to reduce out-of-pocket costs for qualified underinsured patients in the U.S. to no more than $100.

Learn more about Myriad’s financial assistance program »

Myriad myChoice® HRD

What is myChoice HRD?

myChoice HRD includes Tumor BRACAnalysis® for an assessment of both tumor BRCA1 and BRCA2 status as well as the tumor’s Genomic Instability Status, evaluated by three biomarkers associated with homologous recombination deficiency (HRD): LOH (loss of heterozygosity), LST (large-scale state transitions), and TAI (telomeric allelic imbalance). myChoice HRD identifies patients that are most likely to benefit from PARP inhibitors.

Who should be tested with myChoice HRD?

myChoice HRD is currently only available to order for patients with ovarian cancer (including fallopian tube and primary peritoneal cancers) and breast cancer.

What type of sample is needed for the test?

In order for myChoice HRD to be performed, the patient must have formalin-fixed paraffin-embedded tumor blocks or slides that contain at least 40 microns of tumor. The blocks or slides should contain at least 20% tumor by pathologic review.

How do I order myChoice HRD?

myChoice HRD can be ordered by sending a completed myChoice HRD Test Request Form to Myriad. Myriad will then work with your pathologist to collect and test the patient’s tumor.

Download a myChoice HRD Test Request Form »

How long does it take to get a result after I order myChoice HRD?

Most myChoice HRD results are completed in 14 days or less from when we receive the tumor sample at Myriad. Myriad’s customer service team will notify the ordering healthcare provider if results take longer than 21 days.

Does myChoice HRD detect germline and somatic BRCA mutations?

myChoice HRD will detect somatic (isolated to the tumor) and germline (in every cell of the body) BRCA1/2 mutations to inform PARP inhibitor treatment decision making. In order to accurately determine whether a BRCA1/2 mutation identified on tumor testing is germline or somatic, follow up hereditary cancer testing on a blood or saliva/buccal sample should be considered. Myriad has multiple germline follow-up options to accurately determine the mutation type.

Check out our portfolio to find the test that fits your patient’s needs best.

If my patient is negative on Tumor BRACAnalysis testing, do they still need hereditary cancer testing?

myChoice HRD does not assess every gene associated with hereditary cancer, therefore follow up germline testing with Myriad myRisk® may be appropriate to comprehensively assess future cancer risk for your patient and his or her family members.

How are the test results presented?

myChoice HRD provides a separate result for both Tumor BRACAnlaysis and Genomic Instability Status. A patient’s tumor is HR deficient when a BRCA1 or BRCA2 mutation is identified and/or the Genomic Instability Status is positive. A patient’s tumor has a functioning HR pathway (i.e. is HR proficient) when the tumor BRCA1/2 status and genomic instability are BOTH negative.

Will my patient’s insurance cover myChoice HRD testing?

Patients with ovarian cancer are expected to have broad insurance coverage for Tumor BRACAnalysis with myChoice HRD. As always, if a patient encounters ANY financial hardship associated with their bill, Myriad will work directly with the patient toward their complete satisfaction.

BRACAnalysis CDx®

What is BRACAnalysis CDx?

BRACAnalysis CDx is a FDA-approved laboratory developed test to identify germline BRCA1 and BRCA2 mutations and is intended to inform patients’ management related to the PARP inhibitors Lynparza® (olaparib) and Zejula® (niraparib).1,2,3

Who should be tested with BRACAnalysis CDx?

BRACAnalysis CDx is for patients with breast and ovarian cancer who are or may become eligible for treatment with the PARP inhibitor Lynparza® (olaparib). BRACAnalysis CDx can also identify patients with ovarian cancer who may experience enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy.1,2,3

What type of sample is needed for the test?

BRACAnalysis CDx is performed on a blood sample.

How do I order BRACAnalysis CDx?

BRACAnalysis CDx can be ordered by sending a blood sample with the completed test request form in the BRACAnalysis CDx Test Kit to Myriad’s lab.

Order a BRACAnalysis CDx Test Kit »

How long does it take to get a result after I order BRACAnalysis CDx?

Results usually take less than two weeks and are sent to either the ordering healthcare provider or a designated “mail to” provider identified on the test request form.

What is the difference between BRACAnalysis CDx and BRACAnalysis?

Both BRACAnalysis and BRACAnalysis CDx sequence theBRCA1 and BRCA2 genes to determine if there are mutations in either of these genes. BRACAnalysis CDx is the only FDA-approved laboratory developed test that indicates whether or not a patient with breast and ovarian cancer is or may become eligible for treatment with Lynparza® (olaparib). A positive BRACAnalysis CDx result in patients with ovarian cancer is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy.1,2,3

Will my patient’s insurance cover BRACAnalysis CDx testing?

Myriad’s testing services are reimbursed by hundreds of insurance plans. 97% of private insurance companies have coverage for Myriad’s BRCA testing. Although each situation is unique, the average patient pays a coinsurance of less than $54, and 3 out of 4 patients pay $0. As always, if a patient encounters ANY financial hardship associated with their bill, Myriad will work directly with the patient toward their complete satisfaction.

myRisk®

What is myRisk?

Myriad myRisk® Hereditary Cancer is a multi-gene panel that analyzes clinically-significant genes across a number of hereditary cancer syndromes, with a focus on eight primary cancer sites. This test can accurately determine germline status and inform future cancer risks for patients and their family members.

Who should be tested with myRisk?

myRisk can help providers identify patients with an elevated risk for 8 important cancers. In addition, myRisk’s assessment of BRCA1 and BRCA2 can help inform treatment decisions related to PARP inhibitor therapy. To help simplify the process of determining which patients meet criteria for genetic testing, Myriad created the Hereditary Cancer Quiz.

Learn more »

What type of sample is needed for the test?

myRisk can be performed on either a blood or saliva sample.

How do I order myRisk?

myRisk can be ordered by sending a blood or saliva sample with the completed test request form in the myRisk Test Kit to Myriad’s lab.

Order a myRisk Test Kit »

How long does it take to get a result after I order myRisk?

Waiting for results may increase patient anxiety and delay your medical decisions. Myriad believes optimal patient care should include a rapid turnaround-time for test results. Myriad myRisk provides an average turnaround-time of 2-3 weeks.

Will my patient’s insurance cover myRisk testing?

Myriad’s testing services are reimbursed by hundreds of insurance plans. 97% of private insurance companies have coverage for hereditary cancer testing. Although each situation is unique, the average patient pays a coinsurance of less than $54, and 3 out of 4 patients pay $0. As always, if a patient encounters ANY financial hardship associated with their bill, Myriad will work directly with the patient toward their complete satisfaction.

BRACAnalysis®

What is BRACAnalysis?

BRACAnalysis is a genetic test that detects the presence of a BRCA1 or BRCA2 gene mutation. The results of the BRACAnalysis test enable the development of patient-specific medical management plans to significantly reduce the risk of cancer. Additionally, this information can help inform treatment decisions related to PARP inhibitor therapy.

Who should be tested with BRACAnalysis?

BRACAnalysis is for patients who may be at a higher risk of developing cancer based on their personal or family history of cancer. In addition, BRACAnalysis can help inform treatment decisions related to PARP inhibitor therapy. To help simplify the process of determining which patients meet criteria for genetic testing, Myriad created the Hereditary Cancer Quiz.

Learn more »

What type of sample is needed for the test?

BRACAnalysis can be performed on either a blood or buccal sample.

How do I order BRACAnalysis?

BRACAnalysis can be ordered by sending a blood or buccal sample with the completed test request form in the BRACAnalysis Test Kit to Myriad’s lab.

Order a BRACAnalysis Test Kit »

How long does it take to get a result after I order BRACAnalysis?

Waiting for results may increase patient anxiety and delay your medical decisions. Myriad believes optimal patient care should include a rapid turnaround-time for test results. BRACAnalysis provides an average turnaround-time of 2-3 weeks.

Will my patient’s insurance cover BRACAnalysis testing?

Myriad’s testing services are reimbursed by hundreds of insurance plans. 97% of private insurance companies have coverage for hereditary cancer testing. Although each situation is unique, the average patient pays a coinsurance of less than $54, and 3 out of 4 patients pay $0. As always, if a patient encounters ANY financial hardship associated with their bill, Myriad will work directly with the patient toward their complete satisfaction.

Sources:

  1. Intended Use: BRACAnalysis CDx® is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR.Results of the test are used as an aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants, who are or may become eligible for treatment with Lynparza® (olaparib). Detection of deleterious or suspected deleterious germline BRCA variants by the BRACAnalysis CDx test in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy. This assay is for professional use only and is to be performed only at 320 Wakara Way, Salt Lake City, UT 84108.
  2. For more detailed information about Lynparza and its safety and efficacy please go to lynparza.com
  3. For more detailed information about Zejula and its safety and efficacy please go to zejula.com

Lynparza is a registered trademark of the AstraZeneca group of companies. Zejula is a registered trademark of Tesaro, Inc.